健择+顺铂方案治疗晚期非小细胞肺癌临床疗效观察

Therapeutic efficacy of gemcitabine combined with cisplatin for advanced non-small cell lung cancer

目的 观察健择联合顺铂治疗晚期非小细胞肺癌的疗效和毒副作用。方法 对 3 0例Ⅲ期及Ⅳ期的非小细胞肺癌患者 ,于第 1天和第 8天给予健择 (gemcitabine ,GEM ) 12 0 0mg m2 ,静脉输注 ;第 1天顺铂 (cis dichlorodiamineplati num ,DDP) 10 0mg m2 ,静脉输注 ;第 1天和第 8天或为DDP 3 0mg m2 ,静脉输注。 2 8d为 1个周期。结果 全组完全缓解(completeresponse ,CR) 2例 ,部分缓解 (partialresponse ,PR) 12例 ,无变化 (nochange ,NC) 11例 ,进展 (progressiondisease ,PD) 5例 ,总有效率为 46 67%。初治有效率为 5 2 3 8% ,复治为 3 3 3 3 %。两组经统计学比较 ,差异有显著性 (P <0 0 5 )。毒性反应为白细胞减少和血小板减少。结论 健择联合顺铂治疗晚期非小细胞肺癌疗效较高 ,毒性可耐受。

Objective To evaluate the efficacy and toxicity of the combination of gemcitabine and cisplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods A total of 30 cases of non-small cell lung cancer (stages Ⅲ and Ⅳ) were treated with gemcitabine (1 200 mg/m 2, iv infusion, at 1 and 8 d) and cisplatin (100 mg/m 2, iv infusion, at 1 d or cisplatin at 30 mg/m 2, iv infusion, at 1 and 8 d). The administration course was 28 d. Results An objective response was obtained in 46.67% of patients (2 complete and 12 partial responses), whereas 11 patients had no change and 5 patients were progressive. The response rate was 52.38% in patients with no prior chemotherapy and the response rate of 33.33% was achieved in patients who had been given prior treatment. There was significant difference between the two groups (P<0.05). The main toxicities were leukopenia and thrombocytopenia. Conclusion The combination of gemcitabine and cisplatin is a feasible, well-tolerated, and effective scheme in the treatment of advanced NSCLC.